We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
Read MoreHide Full Article
Key Takeaways
AZN's oncology sales hit $5.6B in Q1 2025, up 13%, led by drugs like Tagrisso, Imfinzi, and Enhertu.
Truqap and Datroway launches in HR HER2- breast cancer show early sales strength and FDA momentum.
AZN eyes pipeline growth with late-stage drugs camizestrant and volrustomig across multiple cancer types.
AstraZeneca (AZN - Free Report) is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales. The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with Merck (MRK - Free Report) for Lynparza.
AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates.
A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $430 million in 2024 and $132 million in the first quarter of 2025. AstraZeneca and partner Daiichi’s drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer in January and for EGFR-mutated non-small cell lung cancer (NSCLC) in June this year. Datroway witnessed encouraging early launch signals in the United States for the breast cancer indication in the first quarter.
Important late-stage oncology candidates in AstraZeneca’s pipeline are camizestrant (HR+ HER2- metastatic breast cancer) and volrustomig (several types of cancers).
AstraZeneca expects continued growth of its oncology medicines in 2025, particularly Tagrisso, Enhertu, Merck-partnered Lynparza and Imfinzi, despite the incremental impact of the Part D redesign. Our estimates for AstraZeneca’s total oncology portfolio suggest a CAGR of around 9% over the next three years.
Competition in the Oncology Space
Other large players in the oncology space are Pfizer (PFE - Free Report) , Merck and Bristol-Myers (BMY - Free Report) .
Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena and the Braftovi-Mektovi combination. Pfizer’s oncology revenues grew 7% in the first quarter of 2025. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
Merck’s key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck’s pharmaceutical sales.
Bristol-Myers’ key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues.
AZN’s Price Performance, Valuation and Estimates
AZN stock has risen 7.8% so far this year compared with an increase of 0.8% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, AstraZeneca is reasonably valued. Going by the price/earnings ratio, the company’s shares currently trade at 14.69 forward earnings, slightly lower than 15.0 for the industry. The stock is also trading lower than its 5-year mean of 17.94.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has declined from $4.50 per share to $4.48 per share over the past 60 days. For 2026, earnings estimates have been stable at $4.98 per share over the same timeframe.
Image: Bigstock
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
Key Takeaways
AstraZeneca (AZN - Free Report) is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales. The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with Merck (MRK - Free Report) for Lynparza.
AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates.
A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $430 million in 2024 and $132 million in the first quarter of 2025. AstraZeneca and partner Daiichi’s drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer in January and for EGFR-mutated non-small cell lung cancer (NSCLC) in June this year. Datroway witnessed encouraging early launch signals in the United States for the breast cancer indication in the first quarter.
Important late-stage oncology candidates in AstraZeneca’s pipeline are camizestrant (HR+ HER2- metastatic breast cancer) and volrustomig (several types of cancers).
AstraZeneca expects continued growth of its oncology medicines in 2025, particularly Tagrisso, Enhertu, Merck-partnered Lynparza and Imfinzi, despite the incremental impact of the Part D redesign. Our estimates for AstraZeneca’s total oncology portfolio suggest a CAGR of around 9% over the next three years.
Competition in the Oncology Space
Other large players in the oncology space are Pfizer (PFE - Free Report) , Merck and Bristol-Myers (BMY - Free Report) .
Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena and the Braftovi-Mektovi combination. Pfizer’s oncology revenues grew 7% in the first quarter of 2025. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
Merck’s key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck’s pharmaceutical sales.
Bristol-Myers’ key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues.
AZN’s Price Performance, Valuation and Estimates
AZN stock has risen 7.8% so far this year compared with an increase of 0.8% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, AstraZeneca is reasonably valued. Going by the price/earnings ratio, the company’s shares currently trade at 14.69 forward earnings, slightly lower than 15.0 for the industry. The stock is also trading lower than its 5-year mean of 17.94.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has declined from $4.50 per share to $4.48 per share over the past 60 days. For 2026, earnings estimates have been stable at $4.98 per share over the same timeframe.
AstraZeneca has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.